RDInvesting Provides Investors with Free In-Depth Equity Reports on ACOR, AEGR, BIIB and ENDP

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

Acorda Therapeutics Inc. (NASDAQ:ACOR - News) shares declined 3.85 percent to close at $32.00 a share Wednesday. The stock traded between $31.70 and $33.48 on volume of 384,085 shares traded. Analysts at FBR Capital have recently initiated coverage on the company with a "market perform" rating. Shares of Acorda Therapeutics have gained approximately 28.0 percent year-to-date.

Find out more about Acorda Therapeutics including full access to the free equity report at:
www.RDInvesting.com/ACOR

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR - News) shares declined 8.65 percent to close at $85.25 a share Wednesday. The stock traded between $83.24 and $101.00 on volume of 1.98 million shares traded. Analysts at FBR Capital have recently initiated coverage on the company with an "outperform" rating. Shares of Aegerion Pharmaceuticals have gained approximately 235.0 percent year-to-date.

Find out more about Aegerion Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/AEGR

Biogen Idec Inc. (NASDAQ:BIIB - News) shares declined 2.14 percent to close at $248.95 a share Wednesday. The stock traded between $246.77 and $254.82 on volume of 934,530 shares traded. Analysts at FBR Capital have recently initiated coverage on the company with a "market perform" rating. Shares of Biogen Idec have gained approximately 70.0 percent year-to-date.

Find out more about Biogen Idec including full access to the free equity report at:
www.RDInvesting.com/BIIB

Endo Health Solutions Inc. (NASDAQ:ENDP - News) shares declined 1.36 percent to close at $44.40 a share Wednesday. The stock traded between $44.18 and $45.17 on volume of 1.21 million shares traded. Analysts at FBR Capital have recently initiated coverage on the company with a "market perform" rating. Shares of Endo Health Solutions have gained approximately 70.0 percent year-to-date.

Find out more about Endo Health Solutions including full access to the free equity report at:
www.RDInvesting.com/ENDP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com